A major limitation of radioimmunotherapy of solid tumors with radiolabeled monoclonal antibodies (mAb) is normal tissue toxicity, especially to the bone marrow. In an attempt to maximize radionuclide deposition into tumor sites while minimizing exposure to the bone marrow, investigators have designed pretarget radioimmunotherapy strategies. This strategy is based on an initial targeting molecule designed to localize at tumor sites with a subsequent low molecular weight radioisotope ligand administered which can bind to the targeting molecule. One pretarget strategy used a bifunctional mAb with one binding site for a tumor antigen and a second binding site for the radioactive ligand (1 -6) . The unlabeled bifunctional antibody was administered and allowed to circulate for several days to achieve optimal tumor deposition. Next, the radioligand was administered and showed a rapid tissue distribution and short plasma half-life. This strategy allowed tumor localization of the radioligand to occur rapidly, in a matter of a few hours, with limited radiation doses to the bone marrow. This approach improved radioisotope delivery to tumors in animal models and enhanced scintigraphic imaging in man. A drawback of this design is that the single antigen combining site for tumor antigen resulted in a compromised binding affinity.
A second pretarget strategy took advantage of the highaffinity streptavidin-biotin system by conjugating one of the pair to a mAb for targeting and the other member of the pair in a radioligand preparation. In this way, the mAb retained its affinity for tumor antigen while the short-lived radioligand had high binding affinity to the mAb conjugate (1, 3, 7 -9) . This design seemed to be attractive in animal models and with imaging studies in man. A major drawback was the highaffinity binding of radioligand with any residual mAb in the plasma or extravascular space. The use of an additional step (9 -12) to clear circulating unbound antibody conjugates improved the biodistribution of the radioligand. More recently, this three-step pretarget regimen was modified to use a novel targeting molecule generated by recombinant DNA technology (13 -15) . A genetic construct composed of a single-chain antibody linked to a single chain of streptavidin when transfected in E. coli for protein production forms stable tetramers composed of four single-chain antibodies fused to a streptavidin molecule (four-chain molecule). This reagent has four antigen combining sites and 4 biotin binding sites with a molecular weight of 176,000 Da. It has been used quite effectively in animal model systems of lymphoma and colon cancer using anti-CD20 antibody (B9E9) and anti -tumorassociated glycoprotein 72 (TAG-72) antibody (CC49) constructs (13, 14) . The anti-CD20 fusion protein did well in a pilot clinical trial of pretarget radioimmunotherapy in nonHodgkin's lymphoma (16) whereas the CC49 fusion protein was studied in a pilot trial of pretarget radioimmunotherapy in metastatic colon cancer (17) .
Our ongoing experience with i.p. radioimmunotherapy for recurrent or relapsed ovarian cancer (18) led us to consider a pretarget radioimmunotherapy strategy for regional therapy. This strategy has previously been tested as a regional (i.p.) treatment (19) and motivated us to examine the CC49 fusion protein as an i.p. component of the three-step pretarget regimen in an i.p. TAG-72-positive LS174T tumor model (20, 21) .
Materials and Methods
Production of CC49 fusion protein and biotin clearing agent. Schlom and his group at the National Cancer Institute developed murine CC49 as a second-generation, high-affinity anti-TAG-72 molecule (22) which has been used in phase I trials in ovarian cancer (23) . This genetically engineered molecule retained high binding affinity to TAG-72 with excellent tumor localization and therapeutic efficacy (22, 24) . We have produced the CC49 fusion protein composed of four CC49 single-chain antibodies linked to streptavidin. A genetic fusion of the single-chain variable regions (scFv) of murine anti-TAG-72 antibody (CC49) to a single chain of genomic streptavidin of Streptomyces avidinii was produced. The scFv gene consists of the V H and V L regions, which are separated by a 25-mer Gly 4 Ser linker. The fusion gene encodes a mature protein of 423 amino acids with a calculated monomeric molecular weight of 43,971. The tetrameric structure is due to the streptavidin component, which spontaneously forms a soluble, stable homotetramer on secretion into the E. coli periplasm. The fusion protein has a molecular weight of 176,000 Da with four antigen-binding sites and four biotin-binding sites. Methods for CC49 fusion expression and purification are previously described (13, 14) . Functional characterization was assessed by immunoreactivity and biotin binding/dissociation assays. A competitive immunoreactivity ELISA assay was used to measure the binding of horseradish peroxidase -labeled murine CC49 whole antibody to bovine submaxillary mucin (Sigma Chemical Co., St. Louis, MO) in the presence of serial dilutions of the CC49 fusion protein. Binding of CC49 fusion protein was specific and the curve exhibited a sigmoidal shape, consistent with the one-site competition model. Biotin binding capacity and biotin dissociation rates were determined as previously described (13) . The CC49 fusion protein was capable of binding an average of 3.7 biotins as compared with 4.0 biotin binding sites for recombinant streptavidin. The biotin dissociation rate of CC49 fusion protein was identical to that of recombinant streptavidin (T 1/2 = 397 and 371 minutes, respectively), indicating full functional biotin binding.
The synthetic clearing agent, provided by NeoRx Corp. (Seattle, WA), consists of a bifunctional moiety with multiple N-acetyl-galactosamine residues linked to biotin (MW f 8,652; ref. 15) . The synthetic clearing agent binds rapidly to the streptavidin moiety in the circulating CC49 fusion protein and the carbohydrate interacts with a high-affinity asialoglycoprotein receptor on hepatocytes, resulting in rapid removal from blood, with internalization and catabolism of the fusion protein/ synthetic clearing agent complex in liver cells (15, 16) . Prior studies have shown no difference in biotin localization if animals received low dose (15 Ag) or high dose (900 Ag) of synthetic clearing agent, supporting no effect of synthetic clearing agent on tumor fusion protein retention (15) .
Radiolabeling and binding of CC49 fusion protein and DOTA-biotin. CC49 fusion protein was labeled with 125 I (New England Nuclear, N. Bilerica, MA) by the Iodogen procedure (25) to a specific activity of 10.0 mCi/mg and showed a single peak by size exclusion highperformance liquid chromatography corresponding to the molecular weight of 176,000. The immunoreactivity of the radiolabeled CC49 fusion protein was assessed using bovine submaxillary mucin (Sigma Chemical). The bovine submaxillary mucin was immobilized onto solid support (6.2-mm polystyrene beads; Precision Glass, Chicago, IL) at a concentration of 10 Ag/bead. A single bead was incubated for 1 hour in duplicate with 1 ng of radiolabeled antibody diluted in 1% bovine serum albumin at a concentration of 10 ng/mL in the absence and presence of increasing concentrations of unlabeled fusion protein. The beads were then washed with 4 mL of PBS. The radioactivity remaining on each bead was counted on a gamma counter and percent binding was calculated. (9) and showed >90% binding to avidin-coated beads by passing a known amount of radiolabeled fusion protein through an avidin-coated bead column and calculating percent binding.
Cell line. The LS174T human colon cancer cell line was obtained from the American Type Culture Collection (Herndon, VA). The cells were maintained in Eagle's MEM + 10% fetal bovine serum, L-glutamine, and nonessential amino acids at 37jC and 5% CO 2 .
Biodistribution and imaging studies. In-or 177 Lu-DOTA-biotin. For biodistribution experiments, animals were sacrificed and tissues counted on a well-type gamma scintillation counter with results expressed as % of injected dose (ID)/g of tissue. Based on prior animal studies of pretarget radioimmunotherapy and preliminary studies, the pretarget format was i.p. administration of 800 Ag of CC49 fusion protein followed 20 hours later by 100 Ag of synthetic clearing agent (i.v.) and radiolabeled DOTA-biotin (5 mg) 4 hours post synthetic clearing agent. Subsequent time points were expressed as duration from DOTA-biotin administration.
Intraperitoneal tumor model. Athymic nude mice were injected i.p. with 5 Â 10 7 LS174T cells. At 9 days after tumor injection, the pretarget regimen for biodistribution, imaging, or therapy was initiated. For therapy studies, survival analysis was conducted for each experiment. Kaplan-Meier survival curves were constructed per treatment group, then plotted and compared, and median survival times were computed. A log-rank test (26) was conducted to examine differences in survival between groups. If the overall log-rank test was significant (P < 0.05) over all groups, pairwise comparisons were also conducted. In the event that an animal's survival time was greater than the time of study termination, the day of study termination was substituted for that animal's survival time and treated as censored in the analysis. The great majority of the animals survival times were not censored (i.e., most died before study termination, resulting in very few censored values). In-DOTA-biotin (5 mg) administered i.v. or i.p. 4 hours later. As seen in Fig. 1 , the i.p. route had greater tumor localization than the i.v. route, probably reflecting the rapid excretion of intravascular DOTA-biotin.
To examine the biodistribution of the CC49 fusion protein (targeting agent) as compared with the radiolabeled DOTAbiotin, CC49 fusion protein was labeled with 125 I and DOTAbiotin was radiolabeled with 111 In using the format described above with both agents administered by i.p. route. As seen in Fig. 2A , the 125 I-CC49 fusion protein had its primary sites of localization in the liver (4.7% ID/g) at 24 and 48 hours, reflecting the hepatic clearance of the synthetic clearing agent-CC49 fusion complex, and in the tumor (12.1% ID/g) at 24 hours, reflecting the binding of CC49 fusion protein to tumor TAG-72 antigen. In contrast (Fig. 2B) , the biodistribution of 111 In-DOTA-biotin had tumor localization of 43% ID/g and 44% ID/g at 4 and 24 hours, reflecting the biotin binding to tumor-bound CC49 fusion protein (streptavidin). The highest normal tissue exposure was the kidney with 6% ID/g at 48 and 72 hours, reflecting the urinary excretion of DOTA-biotin. The low liver uptake of DOTA-biotin (f2% ID/g) reflects the intracellular location of the synthetic clearing agent-CC49 fusion complex (16) . This experiment illustrates well the amplification of isotope delivery to tumor and low normal tissue exposure of the low molecular weight isotope carrier molecule (800 Da).
Imaging and biodistribution of 177 Lu-DOTA-biotin following CC49 fusion protein. To examine a second radioisotope, 100 ACi of 177 Lu-DOTA-biotin were used in the same pretarget schema. Figure 3 illustrates the excellent localization in tumor nodules (37.7 F 8.3% ID/g and 22.6 F 8.3% ID/g at 5 hours postinjection; 17.7 F 13.8% ID/g and 25.2 F 11.5% ID/g at 24 hours postinjection) with minimal normal tissue exposures. Figure 4A and B illustrates the excellent imaging of multiple i.p. tumor nodules.
Animal tumor therapy studies with . From other independent studies with same amount of cells injected in the same kind of mice, the median survival for 26 untreated control mice was 29 days (95% confidence interval, 28-33 days). A repeat study using pretarget radioimmunotherapy with 400 and 600 ACi 90 Y-DOTA-biotin had median survivals of 53 and 54 days, which were significantly longer than controls (P = 0.03), and a third experiment using 400 ACi 90 Y-DOTA-biotin had a median survival of 57 days, which was significantly longer than controls (P < 0.01). Thus, the most effective dose with least radionuclide toxicity was in the 400 to 600 ACi range.
Animal tumor therapy studies with 177 Lu-DOTA-biotin. Mice bearing i.p. LS174T tumors underwent pretarget radioimmunotherapy at 9 days after tumor cell injection via administration of 800 Ag of CC49 fusion protein i.p., 100 Ag of synthetic Lu-DOTA-biotin at 5 (n) and 24 ( ) hours after i.p. injection in athymic nude mice bearing LS174T peritoneal tumors following pretargeting with 800 Ag unlabeled CC49 fusion protein i.p. and 100 Ag synthetic clearing agent i.v. 4 hours later. HT, heart; LI, liver; ST, stomach; LI, large intestine; SI, small intestine; CE, cecum; SP, spleen; LU, lung; L KI, left kidney; R KI, right kidney; MU, muscle; BL, blood; RO, reproductive organs; TU MN, main tumor bound to small intestine; TU OT, other i.p. tumors. Lu-DOTA-biotin had median survivals of 57 and 60 days, respectively, which were significantly longer than seen with controls (37 days; P < 0.001). The median survival for the animals treated with 800 ACi 177 Lu-DOTA-biotin was 57 days (95% confidence interval, 57-60 days) whereas the median survival for the animals treated with 400 ACi 90 Y-DOTA-biotin (Fig. 4 ) was 48 days (95% confidence interval, 38-54 days). Based on a log-rank test, the difference is significant (P = 0.026).
Discussion
Prior studies by our group have shown good tumor localization by radiolabeled CC49 to a variety of tumor types (27 -29) without evidence of localization to normal gastrointestinal tissues (23) . This supported the hypothesis that a pretargeting strategy based on CC49 would provide less crossreactivity with normal tissues (gastrointestinal mucosa) than was previously seen with pretargeting based on NR-LU-10 antibody (30) . Toward this end, we have produced a novel tetrameric fusion protein composed of four chains of CC49 scFv and streptavidin. This study has examined this fusion protein and radiolabeled DOTA-biotin given by the i.p. (regional) route.
Prior clinical trials have administered radiolabeled mAb i.p. as a single agent for the treatment of ovarian cancer (23, 31 -33) and in combination with Taxol as a radiosensitizer (18, 34) . These trials had evidence of antitumor efficacy thought to be due to a favorable therapeutic ratio achieved following regional administration. Despite the regional route of delivery, bone marrow suppression was the dose-limiting toxicity. In the pretargeting approach described in this report, fusion protein was administered i.p. and allowed to localize in tumor. The fusion protein was then eliminated from the circulation with a clearing agent and the radiolabeled small molecule (DOTA-biotin) was administered. The latter was bound to the pretargeted fusion protein in the tumor and the remaining radioactivity was rapidly eliminated from normal tissues by renal excretion.
The pretarget protocol described here resulted in high tumor uptake of both preadministered CC49 fusion protein and radiolabeled DOTA-biotin following regional i.p. administration. The i.p. route of radiolabeled DOTA-biotin was superior to an i.v. route of administration. Furthermore, the high tumor/ normal tissue uptake of radiolabeled ( 111 In or 177 Lu) DOTAbiotin was sufficient to provide high-contrast images of multiple tumor nodules throughout the peritoneum, which was validated at necropsy. The level of uptake of radiolabeled DOTA-biotin was substantially less in normal tissues than in tumors as determined by gamma counting. 90 Y is currently being studied as a radioimmunotherapy isotope because of its favorable characteristics, which include a 64-hour half-life and a relatively high h energy (2. In/ 90 Y-DOTA-biotin (the former for imaging and the latter for therapy) is a very attractive option. These can both be bound by DOTA-biotin and generally produce similar biodistributions (35) . The preliminary pretargeting therapy results obtained with 90 Y-DOTA-biotin against the peritoneal LS174T tumor model are promising. There was extended animal survival obtained with 400 or 600 ACi 90 Y-DOTAbiotin whereas higher doses produced toxicity. This is a similar dose range for marrow suppression previously reported for pretargeting with the CC49 fusion protein and 90 Y-DOTAbiotin (14) .
A second option is 177 Lu, which also has a potential for therapy in this pretargeting protocol (36) . 177 Lu is a rare earth element (lanthanide) with a physical half-life of 6.7 days and with intermediate energy and range h emissions (average energy of 133 keV, maximum energy of 497 keV) that penetrate 0.2 to 0.3 mm in soft tissue. 177 Lu also emits two 6 . Survival of nude mice bearing peritoneal LS174T tumors injected i.p. with 800 Ag unlabeled CC49 fusion protein followed by 100 Ag synthetic clearing agent i.v. and treated with 400 or 800 ACi relatively low-abundance, low-energy g rays (113 and 208 keV) that allow imaging with a gamma camera. It is possible that 177 Lu-DOTA-biotin will produce less normal tissue toxicity than 90 Y-DOTA-biotin in radiosensitive tissues such as bone marrow, gastrointestinal tract, and kidney. In the initial study, 600 or 800 ACi 177 Lu-DOTA-biotin produced prolonged survival as compared with control animals, similar to that seen with 90 Y-DOTA-biotin. 177 Lu-DOTA-biotin seemed less toxic than 90 Y-DOTA-biotin. At the 800 ACi dose, 90 Y-DOTA-biotin caused 60% early (toxic) deaths whereas this dose produced no evidence of toxicity with 177 Lu-DOTAbiotin.
In conclusion, these preclinical results suggest that the threestep pretarget radioimmunotherapy strategy is applicable to regional therapy of i.p. tumor sites. Bone marrow suppression will need to be monitored along with toxicity to other key organs including the gastrointestinal tract, kidney, and liver. These studies support the development of a regional pretarget radioimmunotherapy strategy for recurrent or relapsed ovarian carcinoma.
